Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
Perioperative Dexamethasone on Postoperative Outcome in IBD
- Conditions
- DexamethasoneInflammatory Bowel DiseasesPostoperative ComplicationsPostoperative Ileus
- Interventions
- Drug: Normal salineDrug: Dexamethasone
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- Jinling Hospital, China
- Target Recruit Count
- 302
- Registration Number
- NCT03456752
- Locations
- 🇨🇳
Department of Generay Surgery, Jinling hosptal, Medical School of Nanjing University, Nanjing, Jiangsu, China
Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy
- Conditions
- Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 15
- Registration Number
- NCT03457142
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸St. Francis Hospital, East Hills, New York, United States
🇺🇸Good Samaritan Hospital, West Islip, New York, United States
Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Fondazione EMN Italy Onlus
- Target Recruit Count
- 9
- Registration Number
- NCT03440411
- Locations
- 🇮🇹
Fondazione EMN Italy Onlus, Torino, Italy
A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 61
- Registration Number
- NCT03439293
- Locations
- 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Pacific Cancer Medical Center, Anaheim, California, United States
🇺🇸Research Medical Center - Kansas City, Kansas City, Missouri, United States
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
- Conditions
- Relapsed/RefractoryMultiple Myeloma
- Interventions
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT03439280
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸City of Hope - Duarte, Duarte, California, United States
🇺🇸Weill Cornell Medical Center, Div. of Hematology Medical Oncology, New York, New York, United States
Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy
- Conditions
- Post-operative Nausea and VomitingLaparoscopic Sleeve Gastrectomy
- Interventions
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Stony Brook University
- Target Recruit Count
- 83
- Registration Number
- NCT03435003
- Locations
- 🇺🇸
Stony Brook University Hospital, Stony Brook, New York, United States
Aromatherapy for Prevention of Intrathecal Morphine Induced Nausea and Vomiting
- Conditions
- Post Operative Nausea and Vomiting
- Interventions
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2019-04-18
- Lead Sponsor
- Universiti Kebangsaan Malaysia Medical Centre
- Target Recruit Count
- 155
- Registration Number
- NCT03434340
- Locations
- 🇲🇾
Universiti Kebangsaan Malaysia Medical Centre, Cheras, Kuala Lumpur, Malaysia
A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone
- Conditions
- Relapsed and/or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 295
- Registration Number
- NCT03433001
- Locations
- 🇯🇵
Takeda Selected Site, Tokyo, Japan
Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC
- Conditions
- Metastatic Prostate Cancer
- Interventions
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 24
- Registration Number
- NCT03432949
- Locations
- 🇨🇦
University Health Network, Toronto, Ontario, Canada
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
- Conditions
- Clonal Cytopenia of Undetermined SignificanceHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell LymphomaRecurrent Hodgkin LymphomaRecurrent LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory LymphomaChronic Myelomonocytic Leukemia
- Interventions
- Dietary Supplement: Ascorbic AcidDrug: CarboplatinDrug: DecitabineDrug: CisplatinDrug: CytarabineDrug: DexamethasoneDrug: EtoposideDrug: Gemcitabine HydrochlorideProcedure: Central Venous Cannula InsertionDrug: IfosfamideOther: Laboratory Biomarker AnalysisOther: Placebo AdministrationProcedure: Portacath PlacementOther: Questionnaire AdministrationBiological: RituximabDrug: OxaliplatinProcedure: Biospecimen CollectionProcedure: Core BiopsyProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: EchocardiographyProcedure: Positron Emission TomographyProcedure: Magnetic Resonance ImagingProcedure: Computed Tomography
- First Posted Date
- 2018-02-01
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 80
- Registration Number
- NCT03418038
- Locations
- 🇺🇸
Mayo Clinic Health System-Eau Claire Clinic, Eau Claire, Wisconsin, United States
🇺🇸Mayo Clinic Health Systems-Mankato, Mankato, Minnesota, United States
🇺🇸Mayo Clinic Health System-Franciscan Healthcare, La Crosse, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.